Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry

dc.contributor.authorAbonour, Rafat
dc.contributor.authorWagner, Lynne
dc.contributor.authorDurie, Brian G.M.
dc.contributor.authorJagannath, Sundar
dc.contributor.authorNarang, Mohit
dc.contributor.authorTerebelo, Howard R.
dc.contributor.authorGasparetto, Cristina J.
dc.contributor.authorToomey, Kathleen
dc.contributor.authorHardin, James W.
dc.contributor.authorKitali, Amani
dc.contributor.authorGibson, Craig J.
dc.contributor.authorSrinivasan, Shankar
dc.contributor.authorSwern, Arlene S.
dc.contributor.authorRifkin, Robert M.
dc.contributor.departmentMedicine, School of Medicineen_US
dc.date.accessioned2019-06-07T13:53:09Z
dc.date.available2019-06-07T13:53:09Z
dc.date.issued2018-12
dc.description.abstractMaintenance therapy after autologous stem cell transplantation (ASCT) is recommended for use in multiple myeloma (MM); however, more data are needed on its impact on health-related quality of life (HRQoL). Presented here is an analysis of HRQoL in a Connect MM registry cohort of patients who received ASCT ± maintenance therapy. The Connect MM Registry is one of the earliest and largest, active, observational, prospective US registry of patients with symptomatic newly diagnosed MM. Patients completed the Functional Assessment of Cancer Therapy-MM (FACT-MM) version 4, EuroQol-5D (EQ-5D) questionnaire, and Brief Pain Inventory (BPI) at study entry and quarterly thereafter until death or study discontinuation. Patients in three groups were analyzed: any maintenance therapy (n = 244), lenalidomide-only maintenance therapy (n = 169), and no maintenance therapy (n = 137); any maintenance and lenalidomide-only maintenance groups were not mutually exclusive. There were no significant differences in change from pre-ASCT baseline between any maintenance (P = 0.60) and lenalidomide-only maintenance (P = 0.72) versus no maintenance for the FACT-MM total score. There were also no significant differences in change from pre-ASCT baseline between any maintenance and lenalidomide-only maintenance versus no maintenance for EQ-5D overall index, BPI, FACT-MM Trial Outcomes Index, and myeloma subscale scores. In all three groups, FACT-MM, EQ-5D Index, and BPI scores improved after ASCT; FACT-MM and BPI scores deteriorated at disease progression. These data suggest that post-ASCT any maintenance or lenalidomide-only maintenance does not negatively impact patients' HRQoL. Additional research is needed to verify these findings.en_US
dc.eprint.versionFinal published versionen_US
dc.identifier.citationAbonour, R., Wagner, L., Durie, B., Jagannath, S., Narang, M., Terebelo, H. R., … Rifkin, R. M. (2018). Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry. Annals of hematology, 97(12), 2425–2436. doi:10.1007/s00277-018-3446-yen_US
dc.identifier.urihttps://hdl.handle.net/1805/19556
dc.language.isoen_USen_US
dc.publisherSpringeren_US
dc.relation.isversionof10.1007/s00277-018-3446-yen_US
dc.relation.journalAnnals of Hematologyen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.sourcePMCen_US
dc.subjectCommunity medicineen_US
dc.subjectMultiple myelomaen_US
dc.subjectQuality of lifeen_US
dc.subjectRegistryen_US
dc.subjectStem cell transplantationen_US
dc.titleImpact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registryen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
277_2018_Article_3446.pdf
Size:
744.32 KB
Format:
Adobe Portable Document Format
Description:
Main article
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: